Neurocrine Biosciences NBIX
-
-
-
已收盤:-
本益比明細
年季 | 收盤價 | 本業佔比% | 本益比(近四季) | 每股稅後盈餘(元) | 營業利益(千) | 稅後純益(百萬) |
---|---|---|---|---|---|---|
2025Q1 | 110.60 | 52.10 | 32.31 | 0.08 | 23,600 | 8 |
2024Q4 | 136.50 | 86.32 | 40.49 | 1.00 | 142,000 | 103 |
2024Q3 | 115.22 | 88.71 | 30.15 | 1.25 | 183,800 | 130 |
2024Q2 | 137.67 | 122.70 | 37.48 | 0.62 | 145,400 | 65 |
2024Q1 | 137.92 | 292.06 | 54.96 | 0.42 | 99,300 | 43 |
2023Q4 | 131.76 | 86.48 | 67.78 | 1.46 | 150,300 | 148 |
2023Q3 | 112.50 | 88.69 | 62.28 | 0.82 | 141,200 | 83 |
2023Q2 | 94.30 | 85.98 | 52.16 | 0.98 | 73,600 | 96 |
2023Q1 | 101.22 | 109.39 | 152.76 | -0.79 | -114,200 | -77 |
2022Q4 | 119.44 | 92.49 | 197.29 | 0.89 | 103,400 | 89 |
2022Q3 | 106.21 | 99.77 | 174.53 | 0.70 | 87,800 | 69 |
2022Q2 | 97.48 | -399.27 | 763.67 | -0.17 | 54,700 | -17 |
2022Q1 | 93.75 | 75.61 | 125.06 | 0.14 | 3,100 | 14 |
2021Q4 | 85.17 | 101.97 | 90.18 | -0.07 | -36,300 | -7 |
2021Q3 | 95.91 | 98.23 | 0.23 | 44,500 | 23 | |
2021Q2 | 97.32 | 98.59 | 0.43 | 62,800 | 42 | |
2021Q1 | 97.25 | 95.74 | 0.33 | 31,500 | 32 | |
2020Q4 | 95.85 | 130.55 | 3.55 | 71,800 | 348 | |
2020Q3 | 96.16 | 106.49 | 50.80 | -0.59 | -44,300 | -58 |
2020Q2 | 122.00 | 64.19 | 0.81 | -4,913,000 | -2,379 |